NCT06846437 2025-03-24
JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer
Shanghai JMT-Bio Inc.
Phase 3 Recruiting
Clinical Trials
1 trialsUnrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants × Ado-Trastuzumab Emtansine × 1 year × Clear all